Skip Navigation


JAC Advance Access originally published online on July 7, 2009
Journal of Antimicrobial Chemotherapy 2009 64(3):665-667; doi:10.1093/jac/dkp233
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/3/665    most recent
dkp233v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lamoth, F.
Right arrow Articles by Marchetti, O.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamoth, F.
Right arrow Articles by Marchetti, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Imipenem underdosing as a cause of persistent neutropenic fever?

Frédéric Lamoth1, Thierry Buclin2, Andres Pascual1, Thierry Calandra1 and Oscar Marchetti1,*

1 Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland 2 Division of Clinical Pharmacology and Toxicology, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland

* Corresponding author. Tel: +41 21 314 10 10 or 26; Fax: +41 21 314 10 18; E-mail: Oscar.Marchetti@chuv.ch

Keywords: blood concentrations , febrile neutropenia , persistent fever

The first 10% of the full text of this article appears below.

Sir,

Clinical trials with the recommended 2 g daily dose (500 mg four times a day) of imipenem in febrile neutropenia have reported success rates of 60–80%.1 Causes of persistent neutropenic fever often remain unexplained, which results in multiple investigations and empirical modifications of antimicrobial therapy.2 The pharmacodynamic parameter predicting the in vivo antibacterial efficacy of β-lactam antibiotics is the proportion of the dosing interval during which plasma concentrations are above the MIC for the causative pathogen (T>MIC). For . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?